The global meningitis genome partnership.

Genomic surveillance of bacterial meningitis pathogens is essential for effective disease control globally, enabling identification of emerging and expanding strains and consequent public health interventions. While there has been a rise in the use of whole genome sequencing, this has been driven predominately by a subset of countries with adequate capacity and resources. Global capacity to participate in surveillance needs to be expanded, particularly in low and middle-income countries with high disease burdens. In light of this, the WHO-led collaboration, Defeating Meningitis by 2030 Global Roadmap, has called for the establishment of a Global Meningitis Genome Partnership that links resources for: N. meningitidis (Nm), S. pneumoniae (Sp), H. influenzae (Hi) and S. agalactiae (Sa) to improve worldwide co-ordination of strain identification and tracking. Existing platforms containing relevant genomes include: PubMLST: Nm (31,622), Sp (15,132), Hi (1935), Sa (9026); The Wellcome Sanger Institute: Nm (13,711), Sp (> 24,000), Sa (6200), Hi (1738); and BMGAP: Nm (8785), Hi (2030). A steering group is being established to coordinate the initiative and encourage high-quality data curation. Next steps include: developing guidelines on open-access sharing of genomic data; defining a core set of metadata; and facilitating development of user-friendly interfaces that represent publicly available data.

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest AM is an employee of the GSK group of companies. AvdE has received grants from Pfizer, consultancy fees paid directly to the institution from GSK and participated in Science Advisory Boards for Pfizer, GSK and Sanofi Pasteur. ER, LG & VS represent Meningitis Research Foundation, which receives grants from Sanofi Pasteur, GSK and Pfizer. JF is an employee of Pfizer Inc and may hold stock/stock options. JL & RB perform contract research on behalf of Public Health England for GSK, Pfizer and Sanofi Pasteur. JV acts as temporal advisor and receives grants for research from Sanofi-Pasteur, Novartis Vaccines, GlaxoSmithKline and Pfizer, payed to his institution. LHH has served as a consultant to GSK, Merck, Pfizer, and Sanofi Pasteur. LS is currently employed by the GSK group of companies and may hold GSK shares as part of her employee remuneration. PO is an employee of Sanofi Pasteur. SDB, HBB, SB, ABB, DAC, LF, OBH, RSH, MJvR, KAJ, BKA, SL, MLF, ML, NM, JM, MCJM, LMS, CMCR, OR, XW, SY and JMS have no conflicts of interest.